Furthermore, the report [12] found that loss of EphA5 resulted in higher expression of cancer stem cell (CSC) markers in HER2-positive breast cancer cells, including CD44+/CD24-/low, NANOG, CD133+. Here, ERBB2 is linked to breast cancer.